A natural compound called THBru helps liver cells lower bad cholesterol by turning on a specific cellular switch (AMPK), but if you block that switch, THBru can't do its job anymore.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim describes a specific mechanistic interaction tested in a controlled in vitro system (HepG2 cells), where AMPK inhibition is a standard experimental tool (e.g., compound like Compound C or siRNA). The use of 'reversed' implies a direct, testable causal intervention, which is appropriate for mechanistic cell studies. The claim does not overgeneralize to humans or in vivo effects, and the language matches the precision of molecular pharmacology studies.
More Accurate Statement
“Tetrahydroberberrubine (THBru) regulates the AMPK/SREBP2/PCSK9/LDL receptor pathway in HepG2 cells, and this regulation is reversed by pharmacological or genetic inhibition of AMPK.”
Context Details
Domain
medicine
Population
in_vitro
Subject
Tetrahydroberberrubine (THBru)
Action
regulates... and is reversed by
Target
the AMPK/SREBP2/PCSK9/LDL receptor pathway in HepG2 cells
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Tetrahydroberberrubine improves hyperlipidemia by activating the AMPK/SREBP2/PCSK9/LDL receptor signaling pathway.
The study found that when they blocked AMPK in liver cells, THBru stopped working — which means THBru needs AMPK to lower bad cholesterol, just like the claim says.